It has been shown to overcome acquired resistance driven by feedback reactivation of the MAPK pathway in a BRAF-overexpressing melanoma cell line model that was resistant to dabrafenib and trametinib in preclinical studies, making it a potential therapeutic choice for patients with resistance to BRAF and MEK inhibitors [122]. This evidence concerns the gene MAP2K7 and melanoma.